Article Text

Download PDFPDF
Clinical round-up
  1. Sophie Herbert1,
  2. Lewis Haddow2
  1. 1GUM/HIV, The Ashwood Centre, Kettering, UK
  2. 2Infection & Population Health, Centre for Sexual Health & HIV Research, University College London, London, UK
  1. Correspondence to Dr Sophie Herbert, GUM/HIV, The Ashwood Centre, Kettering NN15 7PW, UK; sophieherbert{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Abnormal anal cytology on antiretroviral therapy

The Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN)1 looked at the incidence and predictors of abnormal anal cytology in patients established on antiretroviral therapy. Seven hundred HIV-positive participants in four cities in the USA were followed up for a median of 2.1 years. Baseline anal swab collection for cytology and human papilloma virus (HPV) detection was undertaken, and annually thereafter, and participants also completed a behavioural questionnaire. A total of 243/700 participants had negative baseline cytology, and of these, 37% developed abnormalities using the Bethesda system, with an incidence rate of 13.9/100 person-years of follow-up, 95% CI (11.3 to 16.9). Incidence rates were almost twice as high in men who have sex with men (MSM); 17.9 cases/100 person-years (95% CI 13.9 to 22.7) compared 9.4 cases/person-years (95% CI 5.6 to 14.9) for women and 8.9 cases/person-years (95% CI 4.8 to 15.6) for heterosexual men. The group found that persistent HPV 16 or 18 infection …

View Full Text


  • Contributors SH chose and wrote the manuscript. LH assisted.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.